Cyclazocine revisited (original) (raw)

References

  1. Kuhar, M. J. 1993. Neurotransmitter transporters as drug targets: recent research with a focus on the dopamine transporter. Pharmacologist, 35:28–33.
    Google Scholar
  2. Devine, D. P., Leone, P., Pockok, D., and Wise, R. A. 1993. Differential involvement of ventral tegmental mu. delta and kappa receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266:1236–1246.
    PubMed CAS Google Scholar
  3. Spanagel, R., Herz, A., and Shippenberg, T. S. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. USA 89:2046–2050.
    Article PubMed CAS Google Scholar
  4. Jiang, Q., Seyed-Mozaffari, A., Archer, S., and Bidlack, J. M. 1992. Characterization of antinociceptive actions of alkylating derivatives of morphinone: 14β-(thioglycolamido)-7,8-dihydro-morphinone (TAMO) and 14β(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). J. Pharmacol. Exp. Ther. 262, 526–531.
    PubMed CAS Google Scholar
  5. Archer, S., Seyed-Mozaffari, A., Jiang, Q., and Bidlack, J. M. 1994. 14α-14β [Dithiobis(2-oxo-2, 1-ethanediyl)imino]]bis-7,8-dihydromorphinone and 14α-14β-[dithiobis-92-oxo-2,1-ethanediyl)imino]]bis-7,8-dihydro-(cyclopropylmethyl)-normorphine. Chemistry and opioid binding properties. J. Med. Chem. 37, 1578–1585.
    Article PubMed CAS Google Scholar
  6. Archer, S., Glick, S. D., Maisonneuve, I. M., Bidlack, J. M., Xu, J. Y. Teitler, M., Sebastian, A., El-Hamouly, W., and Hutchinson, I. 1996. Suppression of morphine and cocaine self-administration in rats by a mixed mu antagonist-kappa agonist (N-CBM-TAMO) and a long-acting selective D1 antagonist. Bioorg. Med. Chem. Letters, 6:1139–1144.
    Article CAS Google Scholar
  7. Aceto, M. D., Bowman, E. R., Harris, L. S., Woods, J. H., Smith, C. B., Medzihradsky, F., and Jacobson, A. E. 1989. Very longacting antagonists: the 14β-p-substituted cinnamoylmorphinones and their partial agonist codeinone relatives. Arzneim. Forsch. 39, 570–575.
    CAS Google Scholar
  8. Kosten, T. R., Kleber, H. D., and Morgan, L. 1989. Role of opioid antagonists in treating intravenous cocaine abuse. Life, Sci. 44:141–148.
    Article Google Scholar
  9. Mello, N. K. Mendelson, J. K., Bree, M. P., and Lukas, S. E. Buprenorphine suppresses cocaine self-admistration by rhesus monkey. Science, 248, 859–862.
  10. Dichiara, G., and Imperato, A. 1988. Opposite effects of mu and kappa agonists in dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067–1080.
    CAS Google Scholar
  11. Spealman, R. D., and Bergman, J. 1992. Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J. Pharmacol. Exp. Ther. 281, 607–615.
    Google Scholar
  12. Maisonneuve, I. M., Archer, S., and Glick, S. D., 1994. A kappa opioid receptor agonist attenuates cocaine-induced increases in extracellular dopamine in the nucleaus accumbens of rats. Neurosci. Lett. 181, 57–50.
    Article PubMed CAS Google Scholar
  13. Glick, S. D., Maisonneuve, I. M., Raucci, J., and Archer, S., 1994. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681, 147–152.
    Article Google Scholar
  14. Zernig, G., Winger, G. D., Issaevitch, T. Lewis, J. W., and Woods, J. H., 1995. Clocinnamox effects on intravenous self-administration of mu opioid agonists and cocaine by rhesus monkeys: agonist efficacy estimates. Abstr., CPDD Meeting, Scottsdale AZ, 160.
  15. Archer, S. 1962, Brit. Pat. 611,000.
  16. Harris, L. S., and Pierson, A. K. 1964. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther., 143, 141–148.
    PubMed CAS Google Scholar
  17. Archer, S., Pierson, A. K., Pittman, K., and Aceto, M. 1972. Pharmacological basis of pentazocine, pages 282–285,in Janzen, R., Keidel, W. D., Herz, A. S., Streichle, C., (eds.), Pain, George Theime, Publishers, Stuttgart.
    Google Scholar
  18. De Kornfeld, T. J., and Lasgna, L. 1962. Win 20740, a potent new analgesic. Fed. Proc. 22:248.
    Google Scholar
  19. Martin, W. R., Fraser, H. F., Gorodetsky, C. W., and Rosenberg, D. E., 1965. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl 2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine), Win 20740, ARC II-3). J. Pharmacol. Exp. Ther. 150:426–436.
    PubMed CAS Google Scholar
  20. Martin, W. R., Gorodetzky, and McClane, T. K., 1966. An experimental study in the treatment of narcotic addicts with cyclazocine Clin. Pharmacol. and Ther 455–464.
  21. Fink, M., Freedman, A. M., Esnick, R., and Zaks, A., 1972. Clinical status if the narcotic antagonists in opioid dependence. Agonist and antagonist actions of narcotic analgesic drugs. pages 266–276,in Kosterlitz, H. W., Collier, H. O. J., and Villareal, J. E., (eds.) Macmillan Press.
  22. Resnick, R., Fink, M., and Freedman, A. M. 1971. Cyclazocine treatment of opiate dependence: a progress report. Compr. Psychiat. 12:496–501.
    Article Google Scholar

Download references